This study is for patients with a specific type of head and neck cancer related to a virus called Human Papilloma Virus 16 (HPV16). The aim is to compare two treatments: a combination of a new drug, BNT113, with another drug called pembrolizumab, versus just using pembrolizumab alone. Pembrolizumab helps the immune system fight cancer.
The trial has two parts. Part A checks the safety of the BNT113 and pembrolizumab combination. Part B compares the effectiveness of the combination against pembrolizumab alone. Patients must have cancer that cannot be removed by surgery and that shows a protein called PD-L1.
- Duration: The trial involves multiple visits for treatment and testing.
- Eligibility: You must be 18 or older, have not had certain treatments before, and be able to follow the trial schedule.
- Risks: There may be side effects, and not all patients will receive the combination treatment.
Consider joining if you meet the criteria and are interested in trying a new potential treatment for your cancer.